HC Wainwright Has Optimistic Outlook of CVKD Q2 Earnings

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – HC Wainwright upped their Q2 2026 earnings per share (EPS) estimates for shares of Cadrenal Therapeutics in a report released on Tuesday, July 21st. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.95) for the quarter, up from their previous forecast of ($1.33). HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($5.52) per share. HC Wainwright also issued estimates for Cadrenal Therapeutics’ Q3 2026 earnings at ($0.65) EPS, Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($3.19) EPS and FY2027 earnings at ($3.09) EPS.

Several other research analysts have also recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Friday, July 17th. Wall Street Zen raised Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $13.00.

Cadrenal Therapeutics Stock Performance

Cadrenal Therapeutics stock opened at $2.10 on Thursday. The stock has a market cap of $6.51 million, a P/E ratio of -0.37 and a beta of 1.73. The firm’s fifty day moving average price is $3.70 and its 200-day moving average price is $5.49. Cadrenal Therapeutics has a fifty-two week low of $2.05 and a fifty-two week high of $14.64.

Cadrenal Therapeutics (NASDAQ:CVKD) last posted its earnings results on Thursday, May 7th. The company reported ($1.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.51) by $0.47.

Insider Activity

In related news, CEO Quang X. Pham sold 9,029 shares of the business’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $3.05, for a total transaction of $27,538.45. Following the transaction, the chief executive officer owned 105,989 shares in the company, valued at $323,266.45. The trade was a 7.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 97,500 shares of company stock valued at $388,290 over the last quarter. 26.09% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cadrenal Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. DRW Securities LLC purchased a new stake in Cadrenal Therapeutics in the fourth quarter worth about $171,000. Citadel Advisors LLC purchased a new stake in shares of Cadrenal Therapeutics in the third quarter worth $274,000. JPMorgan Chase & Co. bought a new position in shares of Cadrenal Therapeutics during the third quarter valued at $103,000. Finally, Geode Capital Management LLC raised its position in shares of Cadrenal Therapeutics by 14.3% in the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after purchasing an additional 1,818 shares during the last quarter. 7.92% of the stock is owned by hedge funds and other institutional investors.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.